NCT03708770已完成不适用
everlinQ Endovascular Access System Enhancements (EASE) Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- C. R. Bard
- 入组人数
- 32
- 主要终点
- Number of Participants With Device-Related SAEs
研究概览
简要总结
Prospective, single-center study to evaluate the everlinQ System when used to create an endoAVF in hemodialysis patients.
详细描述
A total of up to 50 subjects will be enrolled and will undergo an endoAVF creation procedure using the everlinQ System. All subjects will be followed for up to 12 months post index procedure based on Investigator's discretion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible for a native arteriovenous fistula.
- •Adult (age >18 years old).
- •Established, non-reversible kidney failure requiring hemodialysis (including pre-dialysis patients).
- •Target vein diameter(s) ≥ 2.0 mm or large enough to accommodate device diameter.
- •Target artery diameter ≥ 2.0 mm or large enough to accommodate device diameter.
- •Estimated life expectancy > 1 year.
- •Patient is free of clinically significant conditions or illness within 30 days prior to the AV fistula that may compromise the procedure
排除标准
- •Known central venous stenosis or central vein narrowing > 50% based on imaging on the same side as the planned AVF creation.
- •Upper extremity venous occlusion(s) and/or vessel abnormality(ies) on the same side as the planned AVF creation that precludes endovascular AVF creation by everlinQ System as deemed by the interventionalists' clinical judgment.
- •Prior surgically created access in the planned treatment location.
- •Functioning surgical access in the planned treatment arm.
- •Pregnant women.
- •New York Heart Association (NYHA) class III or IV heart failure.
- •Hypercoagulable state.
- •Known bleeding diathesis.
- •Immunosuppression, defined as use of immunosuppressive medications used to treat an active condition.
- •Documented history of drug abuse including intravenous drugs within six months of AVF creation.
- •"Planned" concomitant major surgical procedure within 6 months of enrollment or previous major surgery within 30 days of enrollment.
- •Currently being treated with another investigational device or drug.
- •Known allergy to contrast dye which cannot be adequately pre-medicated. CD-0015 Rev 02 - EASE Study Clinical Protocol CONFIDENTIAL Page 8 of 16
- •Known adverse effects to sedation and/or anesthesia which cannot be adequately pre-medicated.
- •Patients who do not have an ulnar or radial artery.
- •At the time of procedure distance between target artery and vein will not allow magnets to align vessels sufficiently to create the fistula.
- •Evidence of active infections on the day of the index procedure.
- •Written informed consent not obtained.
结局指标
主要结局
Number of Participants With Device-Related SAEs
时间窗: 3 months following AVF creation
The safety Endpoint is protocol-defined as Device-Related SAE at 3 months.
Number of Participants With Protocol-Defined endoAVF Maturation
时间窗: Through 6 months post-index procedure
Protocol-defined endoAVF maturation is defined as endoAVF that is free of stenosis or thrombosis, with brachial artery flow at least 500ml/min and at least 4 mm vein diameter (as measured by duplex ultrasound) OR subject was dialized using 2 needles.
次要结局
- Number of Days to Fistula Maturation(Days from Index Procedure)
- Percentage of Participants With Secondary Patency at 6 Months Post-Index Procedure(6 months post-index procedure)
- Number of Endo-AVF-related Re-interventions(At 6 months follow-up)
- Primary Patency at 6 Months Post-index Procedure(6 months post-index procedure)
- Number of Participants With Technical Success(1-7 days following index-procedure)
- Number of Participants Per Catheter Exposure Type(1-7 days, 30 days, 3, and 6 months post-index procedure)
研究者
相似试验
已完成
不适用
everlinQ Endovascular Access Systems Enhancements (EASE-2) StudyChronic Kidney DiseasesNCT03708562C. R. Bard24
终止
不适用
everlinQ endoAVF Post Market StudyChronic Kidney DiseaseNCT02682420C. R. Bard100
已完成
不适用
Novel Endovascular Access Trial (NEAT)Chronic Kidney DiseaseNCT02036671C. R. Bard80
终止
3 期
Veinplicity for Improved Venous Access: The VIVA TrialDifficult-to-access Veins for Intravenous CannulationNCT03752632Physeon GmbH120
已完成
不适用
Percutaneous Less Invasive AV Fistula for Vascular Access in ESRDEnd Stage Renal DiseaseAV FistulaEnd Stage Kidney DiseaseFistulaNCT02363972Medtronic Endovascular103